Non-Opioid Pain Drug LTG-001 Passes Phase 2 Trial, Bringing a New Challenger to the Nav1.8 Race

Severe postoperative pain often forces physicians to weigh pain relief against the risks of opioids. Latigo Biotherapeutics’ oral small molecule LTG-001 has now cleared a key hurdle in a Phase 2 trial: rather than acting directly on the central nervous system, it inhibits Nav1.8 sodium channels on peripheral sensory nerves, aiming to relieve pain while reducing reliance on opioids.

This randomized, double-blind study enrolled 343 patients undergoing abdominoplasty at four centers in the United States. They received high-dose LTG-001, low-dose LTG-001, hydrocodone/acetaminophen, or placebo. The primary endpoint was the summed pain intensity difference over 48 hours (SPID48), which integrates the magnitude and duration of pain improvement; a higher value indicates a better overall analgesic effect.

According to Latigo’s filing with the U.S. Securities and Exchange Commission for its public offering, high- and low-dose LTG-001 improved SPID48 by 62.1 points and 37.8 points, respectively, compared with placebo, with both reaching statistical significance; the hydrocodone/acetaminophen group showed a 40.9-point improvement. Although the high-dose result was numerically higher than that of the opioid comparator group, the disclosures available to date have not demonstrated statistically significant superiority between the two groups. The findings therefore cannot be directly interpreted as showing that LTG-001 provides better pain relief than hydrocodone.

The speed of onset also differed by dose. The median time for patients to achieve meaningful pain relief was 52 minutes with the high dose and 60 minutes with the low dose, compared with 83 minutes for hydrocodone/acetaminophen and 88 minutes for placebo. Both LTG-001 doses increased the proportion of patients who did not require rescue opioids within 48 hours. In the high-dose group, 52.3% used no rescue medication throughout the period, compared with 22.1% in the placebo group, and total rescue opioid use was also significantly reduced.

The safety signals still need to be clarified in larger studies. In the high-dose group, 7% experienced fever and 5.8% experienced presyncope, both more common than in the other groups. Investigators determined that most fevers and all presyncope events were unrelated to treatment, and no new safety signals were identified. However, these attributions currently come primarily from company disclosures, and the trial’s short observation period is also insufficient to fully characterize less common adverse events.

Nav1.8 plays a major role in transmitting peripheral pain signals. Vertex’s suzetrigine, marketed as Journavx, became the first inhibitor of its class approved in the United States in 2025, establishing a regulatory precedent for this development pathway. The LTG-001 data therefore concern more than a single drug candidate, also suggesting that Nav1.8 pain drugs may be moving from a first-in-class product toward competition within the class. However, abdominoplasty is only a soft-tissue pain model and cannot yet represent orthopedic surgery, trauma, or other acute pain settings.

Latigo has applied to raise up to $100 million through an initial public offering and has positioned LTG-001 as its lead program ready to enter Phase 3. The company plans to launch a placebo-controlled bunionectomy trial in the second half of 2026, along with an open-label safety study covering a broader range of clinical settings, with preliminary results expected in the second half of 2027. These two studies will determine whether the current 48-hour signal can extend beyond a single model and become a non-opioid pain relief option with consistent efficacy and acceptable safety.